Interleukin-6 (-174G/C), Interleukin-1β (-511 C/T), and Apolipoprotein B-100 (2488 C/T) Gene Polymorphism in

Muhammad Naveed Najeeb1,2, Umaira Munir2,3, Muhammad Ameer Hamza3

  • 1Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 40100, Punjab, Pakistan.

PubMed

Insights

Genetic variations in Interleukin-6 (IL-6), Interleukin-1 beta (IL-1β), and Apolipoprotein B-100 (Apo B-100) genes were studied in relation to pre-eclampsia. The IL-6 gene polymorphism showed a significant association with the severity of pre-eclampsia in the studied population.

Area of Science:

  • Genetics
  • Obstetrics
  • Immunology

Background:

  • Pre-eclampsia (PE) is a complex pregnancy disorder with significant maternal health risks.
  • Pathogenesis involves factors like placental ischemia, immunological issues, and genetic predispositions.
  • Inflammatory cytokine gene polymorphisms are implicated in PE development.

Purpose of the Study:

  • To investigate the association between IL-6, IL-1β, and Apo B-100 gene polymorphisms and pre-eclampsia.
  • To evaluate the link between these polymorphisms and the severity of pre-eclampsia.

Main Methods:

  • Cross-sectional observational study of 99 pregnant women in Pakistan.
  • Categorization into PE with severe hypertension, PE with hypertension, and control groups.
  • DNA extraction and PCR-RFLP analysis for IL-6, IL-1β, and Apo B-100 gene polymorphisms.

Main Results:

  • Allelic frequencies for IL-6, IL-1β, and Apo B-100 gene polymorphisms differed between pre-eclamptic and control groups.
  • The IL-6 -174 G/C polymorphism was associated with the severity of pre-eclampsia.
  • The IL-6 gene was found to be in Hardy-Weinberg disequilibrium.

Conclusions:

  • Polymorphisms in IL-6, IL-1β, and Apo B-100 genes exhibit varied allele distributions in pre-eclampsia.
  • The IL-6 gene polymorphism is potentially linked to pre-eclampsia severity in the studied Pakistani population.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...